RANI

Rani Therapeutics Holdings, Inc. Class A Common Stock

1.10

USD

RANI Earnings Reports

Positive Surprise Ratio

RANI beat 15 of 18 last estimates.

83%

Next Report

Today AMC

Date of Next Report

Mar 26, 2026

Estimate for Q4 25 (Revenue/ EPS)

$5.10M

-$0.06

Implied change from Q-- -- (Revenue/ EPS)

Implied change from Q4 24 (Revenue/ EPS)

+396.11%

-77.78%

Rani Therapeutics Holdings, Inc. Class A Common Stock earnings per share and revenue

On --, RANI reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.

Looking ahead to Q4 25, -- analysts forecast an EPS of -0.06 USD, with revenue projected to reach 5.10 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Precigen, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.01

Surprise

+88.24%

Absci Corporation Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.19

Actual

-$0.23

Surprise

-16.04%

Candel Therapeutics, Inc. Common Stock

Report Date

Mar 26, 2026 For Q4 25

Estimate

-$0.25

Actual

-$0.54

Surprise

-115.31%

LENZ Therapeutics, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.99

Actual

-$1.15

Surprise

-17.10%

Fennec Pharmaceuticals Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

$0.03

Actual

-$0.11

Surprise

-408.12%

Equillium, Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.06

Actual

-$0.04

Surprise

+35.28%

MaxCyte, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.06

Surprise

+26.47%

Celcuity Inc. Common Stock

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$1.06

Actual

-$0.97

Surprise

+8.72%

TELA Bio, Inc. Common Stock

Report Date

Mar 24, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.16

Surprise

+14.12%

Dyadic International, Inc.

Report Date

Mar 25, 2026 For Q4 25

Estimate

-$0.04

Actual

-$0.06

Surprise

-30.72%

FAQ

What were Rani Therapeutics Holdings, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q-- --?

For Q-- --, Rani Therapeutics Holdings, Inc. Class A Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.

How did the market react to Rani Therapeutics Holdings, Inc. Class A Common Stock's Q-- -- earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is Rani Therapeutics Holdings, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for Mar 26, 2026.

What are the forecasts for Rani Therapeutics Holdings, Inc. Class A Common Stock's next earnings report?

Based on -- analysts, Rani Therapeutics Holdings, Inc. Class A Common Stock is expected to report EPS of -$0.06 and revenue of $5.10M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.